| Market Cap | 167.29K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -4.09M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | - |
| Sales | 771k | PEG | - | EPS past 5Y | - | 200D Avg Chg | - |
| Dividend | N/A | Price/Book | 0.10 | EPS next 5Y | - | 52W High Chg | -50.00% |
| Recommedations | - | Quick Ratio | 1.22 | Shares Outstanding | 152.09M | 52W Low Chg | - |
| Insider Own | - | ROA | -90.30% | Shares Float | 47.04M | Beta | -5.53 |
| Inst Own | - | ROE | -186.43% | Shares Shorted/Prior | -/1.05K | Price | 0.00010 |
| Gross Margin | -223.22% | Profit Margin | - | Avg. Volume | 2,796 | Target Price | - |
| Oper. Margin | -7,300.00% | Earnings Date | - | Volume | 1,000 | Change | 0.00% |
Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.